Jazz Pharmaceuticals, Inc.
NEWS
Here’s a look at some of the stories that emerged from the conference on Wednesday.
Although August is a busy month on the U.S. Food and Drug Administration (FDA)’s calendar for PDUFA dates, this week’s dates were almost all approved ahead of schedule. Here’s a look.
The U.S. Food and Drug Administration (FDA) approved Xywav, the first new treatment option indicated for both cataplexy and excessive daytime sleepiness in people living with narcolepsy in more than 15 years.
Wrapping up the month of July, there are three PDUFA dates on the U.S. Food and Drug Administration (FDA) calendar.
The approval was based on monotherapy clinical data from a trial in 105 adults with SCLC whose disease progressed after platinum-based chemotherapy.
Pharma, biotech and life sciences companies bolster their executive teams and boards with these Movers & Shakers.
The following is a roundup of some of this week’s non-coronavirus biopharma news.
The U.S. Food and Drug Administration accepted the companies’ New Drug Application for lurbinectedin under Priority Review.
Companies from across the globe provide updates on their businesses and pipelines.
JOBS
IN THE PRESS